New developments in pharmacology of vitamin D.
D000927:Anticonvulsants / Q000009:adverse effects; D002762:Cholecalciferol / Q000008:administration & dosage / Q000627:therapeutic use; D004097:Dihydrotachysterol / Q000008:administration & dosage / Q000627:therapeutic use; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004872:Ergocalciferols / Q000008:administration & dosage / Q000627:therapeutic use; D005799:Genes, Dominant; D005808:Genes, Recessive; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use; D007015:Hypophosphatemia, Familial / Q000188:drug therapy / Q000235:genetics; D012279:Rickets / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D012730:Sex Chromosomes; D014807:Vitamin D / Q000009:adverse effects / Q000627:therapeutic use*
D000927:Anticonvulsants; D004100:Dihydroxycholecalciferols; D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D014807:Vitamin D; D002762:Cholecalciferol; D004097:Dihydrotachysterol